WPA
TVTX icon

Wealth Preservation Advisors’s Travere Therapeutics TVTX Stock Holding History

Wealth Preservation Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-59
Closed -$1.75K – 884
2026
Q1 		$1.75K Buy
+59
New +$1.76K ﹤0.01% 610

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealth Preservation Advisors's TVTX Position: Q2 2026 in Review

Wealth Preservation Advisors sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 59 shares — an estimated $1.75K sold.

Wealth Preservation Advisors first reported a position in TVTX in Q1 2026 and held it in 1 quarter. The position peaked at $1.75K in Q1 2026. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Wealth Preservation Advisors reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Wealth Preservation Advisors sold 59 Travere Therapeutics shares in Q2 2026, an estimated $1.75K.
  • Wealth Preservation Advisors first reported a position in Travere Therapeutics in Q1 2026 and held it in 1 quarter.
  • Wealth Preservation Advisors's Travere Therapeutics position peaked at $1.75K in Q1 2026.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Wealth Preservation Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.